Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
Poll: 1 in 8 Adults Say Theyve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease About Half Who Have Taken the Drugs Say It Was Difficult to Afford Even with Insurance About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds
Many patients who expected to be prescribed insulin are now prescribed GLP-1 drugs instead, further blurring the line between the two categories in the public consciousness
Mara Jos Soler is the CKJ Editor-in-Chief and reports honorarium for conferences, consulting fees and advisory boards from AstraZeneca, Novo-Nordsik, Esteve, Vifor, Travere Therapeutics, Bayer, Mundipharma, Ingelheim Lilly, Jansen, ICU Medical and Boehringer
This continuous loop of feedback and support is the backbone of a successful program
1 T2D is characterized by elevated blood sugar levels caused by either insufficient production of insulin or improper insulin function, also referred to as insulin resistance